1 ISA mistake to avoid in 2025

Our writer reveals a very silly mistake he made earlier this year that has reduced the returns for his Stocks and Shares ISA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A young Asian woman holding up her index finger

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With 2025 fast approaching, many are pausing to take stock of 2024. For me, I’ll be looking at the moves I made in my Stocks and Shares ISA, judging which made me money (at least so far), and which didn’t.

Already though, I’m aware of a loss-making error that has taken the shine off my overall portfolio performance.

Here is the ISA mistake I’m keen to avoid repeating in 2025.

Should you invest £1,000 in Moderna right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Moderna made the list?

See the 6 stocks

Doubling down

You don’t have to get it back the way that you lost it.

Warren Buffett

Axon Enterprise has been my biggest winner in 2024. Shares of the Taser maker are up a stunning 154%!

They’ve now surged 782% over five years.

Created with Highcharts 11.4.3Axon Enterprise PriceZoom1M3M6MYTD1Y5Y10YALL15 Dec 201915 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

However, I culled this top performer a while back, taking some profits as it mushroomed into a mammoth holding in my ISA.

Now, there’s nothing inherently wrong with that. It’s still a top position in my ISA (and SIPP), and I’m more than happy with it. It’s how I recycled some of those gains that’s come back to haunt me.

That’s because I added to my holding in mRNA vaccine pioneer Moderna (NASDAQ: MRNA) at the start of 2024. That position has fallen, along with my previous two purchases.

In fact, the stock has crashed 71% in six months and 45% over one year! The stock has turned into a giant red weed in my portfolio.

All in all, I’m down 65% on this share. Ouch.

Created with Highcharts 11.4.3Moderna PriceZoom1M3M6MYTD1Y5Y10YALL15 Dec 201915 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

What’s gone wrong?

Moderna was one of a small handful of companies whose vaccines came to the rescue during the pandemic. Its mRNA platform enabled the rapid creation of Spikevax in record-quick time.

It was the potential scalability of the biotech’s platform, and what diseases it could address outside of Covid (including cancer), that attracted me to the stock. But Moderna’s new vaccine for respiratory syncytial virus (RSV) hasn’t done very well, while Covid sales continue to fall off a cliff.

In August, the firm lowered its annual sales guidance by as much as $1bn, to $3.0bn-$3.5bn. And it doesn’t expect to break even on an operating cash cost basis till 2028, rather than 2026 as originally planned.

Meanwhile, Donald Trump’s nomination of vaccine sceptic Robert F. Kennedy Jr. for a potential political role in health isn’t exactly helping sentiment for the stock. So there are plenty of risks here.

On reflection though, my investment thesis remains just about intact. The company is still targeting 10 product approvals over the next three years, while reducing its cost structure.

Successful product launches aren’t guaranteed. But I’m encouraged that the probability of Moderna’s drug candidates progressing from phase one to phase three trials is roughly six times higher than the biopharma industry average. 

This highlights the exciting potential of the platform. However, the firm will have to start turning promise into performance through better execution for the stock to rebound and do well.

Foolish takeaway

Looking back, what I did was cut the flowers (Axon) to water the weeds (Moderna). That was a cardinal investing mistake, and one which I won’t be repeating again.

Looking ahead, I see plenty of opportunities, whether in growth stocks or high-yield income shares. With careful selection, 2025 could be a year of substantial gains for those ready to seize these opportunities.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Axon Enterprise and Moderna. The Motley Fool UK has recommended Axon Enterprise and Moderna. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »